Web Exclusives

First-Line Toripalimab Combined with Chemotherapy Conveys Significant Benefits in Patients with Esophageal Squamous-Cell Carcinoma

Recently released clinical trial results show that bavituximab in combination with pembrolizumab had promising antitumor activity and was well-tolerated in patients with advanced gastric or gastroesophageal cancer. Read More ›

Progression-Free Survival Improved in Patients with HER2-Negative Recurrent or Advanced Gastric or Gastroesophageal Junction Cancer Receiving Nivolumab plus Chemotherapy

Patients with treatment-naïve advanced or metastatic esophageal squamous-cell carcinoma receiving combination toripalimab and chemotherapy saw significant progression-free survival and overall survival improvement. Read More ›

De-escalating Treatment to Endocrine Monotherapy in Patients with Advanced HR-Positive, HER2-Negative Breast Cancer After Initial Treatment with CDK4/6 Inhibitors

Clinical trial results demonstrate nivolumab combined with chemotherapy conveys improvement in overall response rate and progression-free survival in patients with recurrent or advanced gastric cancer. Read More ›

Assessing Outcomes and Socioeconomic and Racial Disparities Using Data from the National Cancer Institute’s SEER Program

A small study suggests that in select patients with long-lasting disease stabilization, elective discontinuation of CDK4/6 inhibitors is feasible. Read More ›

Evaluating the Effectiveness and Toxicities Associated with Novel Oral Agents Palbociclib and Ribociclib to Understand the Influence of Regimen Changes on Disease Progression

A large retrospective cohort population-based study demonstrated a disproportionate elevation of breast cancer–specific and all-cause mortality among African American women. Read More ›

A Comprehensive Literature Review of Available Real-World Evidence Evaluating CDK4/6 Inhibitors in Patients with HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

For the treatment of patients with HR-positive/HER2-negative metastatic breast cancer, targeting CDK4/6 represents a novel, effective, and safe therapeutic approach in combination with hormone therapy. Read More ›

In CDK4/6 Inhibitor and Endocrine Therapy–Resistant Breast Cancer, Co-Targeting CDK4/6 and AKT with Endocrine Therapy Prevents Progression

CDK4/6 inhibitors were associated with improved outcomes in HR-positive/HER2-negative advanced metastatic breast cancer. Read More ›

Nivolumab Combined with Chemotherapy Improves Survival Outcome in Patients with Advanced Gastric/Esophageal Cancers

Study results suggest the potential of clinical development of estrogen receptor, CDK4/6, and AKT co-targeting strategies after progression on a CDK4/6 inhibitor and endocrine therapy combination, and in tumors showing high phospho-AKT levels. Read More ›

Second-Line Pembrolizumab Therapy Conveys Survival Benefit in Patients with Advanced Esophageal Cancer

CheckMate 649 study results demonstrate that nivolumab combined with chemotherapy has an acceptable safety profile and improves survival outcomes in patients with advanced gastric/esophageal cancer. Read More ›